Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.

Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.

Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.

Join our webinar to discover how to de-risk ADC development through the integration of AI-driven analytics, mouse clinical trials and specialized translational models.

Learn how patient-derived organoids predict treatment response in metastatic colorectal cancer and explore findings from the OPTIC study on drug sensitivity and clinical outcomes.

In this webinar, Rico Buchli, PhD, shares how next-generation soluble HLA peptide discovery platforms can strengthen early immunotherapy R&D – from target identification and confirmation to receptor/drug validation and translational decision-making.

Discover how YUMAB’s pHLA display library identifies highly specific TCR-like antibodies to target undruggable cancer epitopes with improved safety profiles.

Unlock the full potential of photoacoustic imaging (PAI) for evaluation of the tumor microenvironment at VisualSonics’ Advanced Photoacoustic Imaging Workshop.

Hear Dr. Zheng Wei share a comprehensive payload-linker CMC development strategy that covers regulatory guidance, RSM selection, and stage-appropriate quality control to navigate the evolving complexities of ADC design from IND to NDA.

Join us for an insightful webinar exploring Lonza’s comprehensive portfolio of primary human cells and optimized media systems.

Experts at FUJIFILM VisualSonics explore how the Vevo F2 can advance oncology research through high-resolution ultrasound and photoacoustic imaging.

Discover how AI-driven models and patient-derived xenografts are advancing personalized combination therapies for glioblastoma.